Clone:
REA214
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC
Alternative names:
AIRM1, CDw328, D-siglec, QA79, Siglec-7, SIGLEC19P, SIGLECP2, p75, p75/AIRM1

Extended validation for CD328 (Siglec-7) Antibody, anti-human, REAfinity™

Specificity

Knockout validation
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
View details
Overlay histogram showing flow cytometric analysis of CD328 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD328-PE, clone (REA214). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Overlay histogram showing flow cytometric analysis of CD328 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD328-PE, clone (REA214). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD328 (Siglec-7) Antibody, anti-human, REAfinity™

Overview

Clone REA214 recognizes CD328, which is a member of sialic acid-binding immunoglobulin-like lectins (siglecs) family of trans-membrane proteins. Upon recognizing their natural ligands, the sialylated carbohydrates, siglecs generally transmit an inhibitory signal. CD328 is a 75 kDa type I trans-membrane protein and further belongs to the human CD33-related siglec receptors with sialic acid binding N-terminal Ig domain, two C2-set Ig domains, and a cytoplasmic region containing one immune-receptor tyrosine based inhibitory motif (ITIM) and one ITIM-like motif. Expression of CD328 is found on natural killer (NK) cells, monocytes, and on a small subset of CD8
+
/CD3
+
T cells and it preferentially binds (2,8)-linked disialic acids and branched 2,6-sialyl residues.
Additional information: Clone REA214 displays negligible binding to Fc receptors.

Alternative names

AIRM1, CDw328, D-siglec, QA79, Siglec-7, SIGLEC19P, SIGLECP2, p75, p75/AIRM1

Detailed product information

Technical specifications

CloneREA214
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hosthuman cell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD328 (Siglec-7)
Alternative names of antigenAIRM1, CDw328, D-siglec, QA79, Siglec-7, SIGLEC19P, SIGLECP2, p75, p75/AIRM1
Distribution of antigenmonocytes, NK cells
Entrez Gene ID27036
RRIDAB_2657531, AB_2657532, AB_2657533, AB_2657534, AB_2657535, AB_2657536, AB_2657537, AB_2657538, AB_2657539, AB_2657540, AB_2657541, AB_2657542, AB_2657543, AB_2657544, AB_2657545, AB_2922093, AB_2922060, AB_2928422, AB_2928421, AB_2657530

Resources for CD328 (Siglec-7) Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD328 (Siglec-7) Antibody, anti-human, REAfinity™

Publications

  1. Attrill, H. et al. (2006) Siglec-7 undergoes a major conformational change when complexed with the (2,8)-disialylganglioside GT1. J. Biol. Chem. 281: 32774-32783
  2. Angata, T. et al. (2000) Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology 10: 431-438
  3. Madge, P. D. et al. (2016) Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy. Sci Rep 6: 36012

Related products for
CD328 (Siglec-7) Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?